Search | Clinical Trials Finder

Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Placebo (PB); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Glendale, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
Interventions: ALG-055009, Placebo; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 40
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 37 more

Conditions: Hypertension, Adherence, Medication
Interventions: Medication Adherence Problem Solving for Hypertension; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metabolic Dysfunction-associated Steatohepatitis
Interventions: Efimosfermin alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Miami, Florida • Houston, Texas

Conditions: Obesity, Obesity (Body Mass Index >30 kg/m2)
Interventions: Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal Ablation; Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Liver Cirrhosis
Interventions: BI 3802876, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Chandler, Arizona • Coronado, California • La Mesa, California + 21 more

Conditions: Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
Interventions: Not listed
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Timeline: 2025
U.S. locations: 1
States / cities: Lady Lake, Florida

Conditions: MASH
Interventions: RO7790121; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Tucson, Arizona • Marietta, Georgia • Bastrop, Louisiana + 8 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: BMN 349, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: San Diego, California • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Tirzepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Coronado, California • Pasadena, California • Metairie, Louisiana + 3 more

Conditions: NASH With Fibrosis, MASH With Fibrosis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 200
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 61
States / cities: Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 48 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support; Drug · Behavioral
Lead sponsor: City University of New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), MetALD
Interventions: Not listed
Lead sponsor: HRI-MAIL-NIT; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 4 more

Conditions: MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Interventions: Thermoacoustic Enhanced Ultrasound; Device
Lead sponsor: Endra Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions: BI 770371, Placebo for BI 770371; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Coronado, California • Montclair, California + 8 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B); Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 48
States / cities: Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 41 more

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Resmetirom, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 12 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 74
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 60 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin Alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 52
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 41 more

Conditions: MASLD, MASH, Fibrosis, Liver, Chronic Liver Disease
Interventions: Endoscopic Ultrasound Shear Wave Elastography (EUS) and Attenuation Imaging, FibroScan, Liver biopsy; Device
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Danville, Pennsylvania

Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Search by objective public record fields.

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)

Testing Feasibility of Medication Adherence Problem Solving for Hypertension

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

ENLIGHT Trial: ESG With Fundal Mucosal Ablation

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Nutrition Intervention Combined With Resmetirom for MASH

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Assessment of Non-Invasive Testing in Major Liver-Related Outcomes

Thermoacoustic Method for Estimating Liver Fat Fraction

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Guerbet Liver Fibrosis

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Endoscopic Ultrasound Shear Wave Elastography Study

A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population